irAE ICYMI #ASCO25 recap #2: irAEs implications of ICIs 2/2 VEGF inhibitors in adv NSCLC
➡️ 41 pts w/ prior ICI f/b ramucirumab
➡️ Any irAE: OS 8m vs 6m; PFS 7m vs 3m (not significant)
➡️ Delayed irAE: OS 34.5m; PFS 33.5m
irAE ICYMI #ASCO25 recap #1: HBV reactivation in HCC on ICIs + antivirals
➡️ 1015 HBsAg+ pts with HCC started on ICI
➡️ Reactivation risk low w/ antiviral ppx (4.5% vs 6.1%, NS)
➡️ High HBV-DNA titer not an independent OS/PFS risk
📚Since it's #ASPIRE April, we're revisiting #ASCO25 sessions with a series of ICYMI recaps on immune-related adverse events #irAEs
Short takeaways on trial design, numbers, and outcomes from last year's abstracts. Stay tuned! 👇
#Oncology #Immunotherapy
New study: blood test using #cfDNA methylation detects multiorgan damage from immune checkpoint inhibitors — found in all patients with #irAE, sometimes weeks before symptoms. Suggests therapy causes systemic loss of immune tolerance. www.nejm.org/doi/full/10.... @funchainmd.bsky.social
Sign up now! 2026 ASPIRE-IOTOX Symposium at MDAnderson April 24-25, 2026. Join us to discuss #irAE! mdanderson.cloud-cme.com/course/cours... @funchainmd.bsky.social @kerryreynoldsmd.bsky.social @kmittalmd.bsky.social
📢 Join us for ASPIRE Consortium's Global Session 🌍 Collaborating Across Europe: Advancing Care for irAEs
🎙️ Featuring @drjnaidoo.bsky.social + panel
📅 Sept 15, 2025
🕒 Time: 15:00–16:00 (Central US Time)
💻 Zoom Link: partners.zoom.us/j/82978479128
🔢 Meeting ID: 829 7847 9128
@ascocancer.bsky.social
Mark your calendars! ASPIRE-IOTOX Symposium April 24-25, 2026 at MD Anderson Cancer Center #irAE #immunotherapy @sitcancer.bsky.social @ascocancer.bsky.social @funchainmd.bsky.social @kerryreynoldsmd.bsky.social @kmittalmd.bsky.social @mdanderson.bsky.social
Mark your calendars! ASPIRE-IOTOX Symposium April 24-25, 2026 at MD Anderson Cancer Center #irAE #immunotherapy @sitcancer.bsky.social @ascocancer.bsky.social @funchainmd.bsky.social @kerryreynoldsmd.bsky.social @kmittalmd.bsky.social @mdanderson.bsky.social
Check out the Aug 2025 #ASPIRE newsletter to hear the latest in #irAEs. Do not miss our quarterly case conference Tues, Aug 19th at 5:30pm CST. @ascocancer.bsky.social @kerryreynoldsmd.bsky.social @funchainmd.bsky.social @kmittalmd.bsky.social mailchi.mp/759095cedbb0...
📘 Just launched: the first-ever clinical casebook focused solely on immune-related toxicities. 65 expert-contributed cases across 10+ organ systems. Essential reading for the #irAE frontlines. Grab your copy 👉 link.springer.com/book/10.1007...
#irAE #OncologyBooks @ascocancer.bsky.social #ASPIRE
🧠 Stay sharp with the latest in #irAE research! From duplilumab in cutaneous toxicities to survival outcomes with inpatient ICI use—our curated #ASPIRE reading list 🔥.
Start reading now in our latest newsletter: mailchi.mp/325da8534919...
#Immunotherapy #irAE #MedEd @kmittalmd.bsky.social
Missed #ASPIRE June 17 webinar? 🎥 Now available on-demand! Dive into cutting-edge #ASCO updates on #irAE education, biomarkers, & translation. Must watch the evolving #immunotherapy landscape. 🎯 Link in our latest newsletter:
mailchi.mp/325da8534919... @funchainmd.bsky.social
Wrapping up #ASCO24 with this thought: let’s get more people under the survival curve and lift it up - it might be prolonged survival, it might even be cure. Every moment counts.
May we all walk into our post ASCO lives inspired ✨ 📈 @ascocancer.bsky.social @aspire-cop.bsky.social
🚀 That's a wrap #ASCO25! Join ASCO’s #ASPIRE Community of Practice, the go-to hub for clinicians addressing immune-related toxicities!
🌟 FREE access for non-oncologists (for a limited time)
💬 Engage in virtual meetings, expert discussions, and access curated content!
docs.google.com/forms/d/1zfl...
Alright y’all - last day of #irAE content at #ASCO25 @aspire-cop.bsky.social @ascocancer.bsky.social
Monday 6/2
11:30a Bi/Multi-specific Antibodies S406
➡️Giuseppe Curigliano
➡️Enriquita Felip
➡️Funda Meric Bernstam
3p Beyond Checkpoint E450b
➡️me 😇
➡️Evan Lipson
➡️Jason Luke
Phase II ipi nivo rela with IL6 inhibitor sarilumab with ORR 68% - highest reported with IO - and grade 3/4 irAEs 12% - lowest reported with combination IO
Jan Mehnert @nyulangone.bsky.social
#ASCO25 @ascocancer.bsky.social @aspire-cop.bsky.social
Melanoma rapid #3 ➡️ High fiber diet of 30-50g daily is tolerable, pCR 57% in neoadj group, grade 3+ irAE 28.8%
Took 400 patients screened to enroll 45 🤔
Yiufan Qiu @mdanderson.bsky.social
#ASCO25 @ascocancer.bsky.social
@aspire-cop.bsky.social
Melanoma rapid orals #5 ➡️ single dose of neoadj ipi 3 + nivo 1 with 59% major pathological response and 9% grade 3+ TRAE. CD8 PET not predictive.
Sarah Lochrin @mskcc.bsky.social
#ASCO25 @ascocancer.bsky.social @aspire-cop.bsky.social
Neoadj ipi/nivo is clear winner in melanoma, prompting Genevieve Boland and Diwakar Davar to discuss the CONSTANT communication required between med onc/ surg onc (and relevant subspecialists) perioperatively to address ir-AI or colitis #ASCO25 #irAE @ascocancer.bsky.social @aspire-cop.bsky.social
Honoring all those whose lives have been touched by cancer - your story is unique and powerful, I see you!
#NCSD25
Starting soon! More great #irAE content at #ASCO25, including CAR-T and BiTES @kmittalmd.bsky.social @funchainmd.bsky.social @kerryreynoldsmd.bsky.social #ASPIRE
Such important work @aspire-cop.bsky.social team. Crucial to collect the right info to improve our understanding of immunotherapy toxicities and plan the right supportive care for our patients
#IOtox #supportivecare #immunotherapy
Thank you to the @aspire-cop.bsky.social executive committee for giving me the opportunity to present at this exciting education session at @ascocancer.bsky.social #asco25
Starting in 5 min! Be a part of history at the first meeting of @aspire-cop.bsky.social #irAE #ASCO25 @ascocancer.bsky.social
@mazietsangmd.bsky.social describing how to "connect the dots" of #irAE multidisciplinary management across academic and community cancer centers #ASPIRE @ascocancer.bsky.social @funchainmd.bsky.social @kerryreynoldsmd.bsky.social @kmittalmd.bsky.social
Did you know the ICD10 codes to identify patients experiencing immunotherapy toxicity? @kmittalmd.bsky.social presents these codes as a system-based approach to capture #irAE impact @funchainmd.bsky.social @kerryreynoldsmd.bsky.social @mazietsangmd.bsky.social @ascocancer.bsky.social
@kmittalmd.bsky.social presents #ASPIRE #ASCO25 community united in "Advancing Clinical Care, Research, and Advocacy in Immunotherapy-Related Adverse Events" #irAE @funchainmd.bsky.social @kerryreynoldsmd.bsky.social @ascocancer.bsky.social @mazietsangmd.bsky.social @advocatecollab.bsky.social
Kathryn Bollin, MD's #ASCO25 community oncology perspective on "Getting Practical About Care Transitions" in patients with #irAE #OncSky. "Access to immunotherapy has far outpaced evidence to inform how to manage the related side effects" @ascocancer.bsky.social #ASPIRE @pateloncology.bsky.social
